The Beta‐Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Jasmine A Luzum und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Heart Failure, Pharmacogenomic Variants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Previous pharmacogenetic findings for beta‐blocker pharmacodynamic candidate genes ( ADRB1 , ADRB2 , ADRA2C, GRK4, and GRK5) have been inconsistent. Therefore, the purpose of this study was to determine whether interactions of pharmacodynamic variants with beta‐blocker exposure significantly associated with survival in patients with heart failure with reduced ejection (HFrEF). The 893 patients were 51% self‐reported African American and 49% self‐reported White race, 36% female, and 240 died (27%) over a median follow‐up of 2.8 years. The primary outcome was all‐cause mortality. Using Cox proportional hazards models with time‐varying beta‐blocker exposure and adjusted for clinical risk factors and ancestry, interactions of ADRB1 Arg389Gly, ADRB1 Ser49‐Arg389Gly haplotype, ADRA2C Del 322‐325 , and GRK4 Ala486Val with beta‐blocker exposure were significant before correction for multiple comparisons ( p < 0.1), but only GRK4 Ala486Val remained significant in African Americans after correction for multiple comparisons using the adaptive Hochberg method ( p = 0.022). Beta‐blocker exposure only associated with a significant reduction in the risk of mortality in the African American HFrEF patients with the GRK4 Ala486/Ala486 genotype (HR = 0.44; 95% CI = 0.20–0.96; p = 0.04). In conclusion, the interaction of GRK4 Ala486Val with beta‐blocker exposure significantly associated with survival in African American HFrEF patients. Larger sample sizes or meta‐analyses are needed to have more statistical power to better assess beta‐blocker pharmacogenetic interactions for ADRB1 Arg389Gly, ADRB1 Ser49‐Arg389Gly haplotype, and ADRA2C Del 322‐325 in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
- Center for Individualized and Genomic Medicine Research (CIGMA), Henry Ford Health System, Detroit, Michigan, USA.
- Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan, USA.
- Heart and Vascular Institute, Henry Ford Health System, Detroit, Michigan, USA.
ORCID-Profile: Jasmine A Luzum, Shana D R Littleton, Ana I Lopez-Medina, Bin Liu, Ruicong She, David E Lanfear
Zitieren
APA
Luzum, J. A., Littleton, S. D. R., Lopez-Medina, A. I., Liu, B., She, R., & Lanfear, D. E. (2025). The Beta‐Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants. Clinical and Translational Science. https://doi.org/10.1111/cts.70239
Vancouver
Luzum JA, Littleton SDR, Lopez-Medina AI, Liu B, She R, Lanfear DE. The Beta‐Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants. Clinical and Translational Science. 2025. doi:10.1111/cts.70239
BibTeX
@article{Luzum2025,
author = {Luzum, Jasmine A and Littleton, Shana D R and Lopez-Medina, Ana I and Liu, Bin and She, Ruicong and Lanfear, David E},
title = {The Beta‐Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70239}
}
EUVIMED